Annual Results 2021

Geraldine Matchett & Dimitri de Vreeze

Co-CEOs Royal DSM


Annual General Meeting Heerlen, 10 May 2022

HEALTH · NUTRITION · BIOSCIENCE






Over two decades, DSM has transformed into a pure play health, nutrition and bioscience company





DSM has more than 150 years of deep scientific heritage, with bioscience facilities around the world







- DSM is active in the major groups of biosciences including microbial technologies with bacteria, yeasts, fungi and microalgae
- Close to 50% of DSM's current (2021) sales of nutritional ingredients is produced out of biobased and/or input materials directly extracted from nature



Leadership in Health, Nutrition & Bioscience enhanced through high quality M&A




Added new product categories, building the most comprehensive portfolio of nutritional ingredients

Strengthened bioscience capabilities and expanded global reach

Built a unique business model with solutions/premix and extended this into precision and personalization




DSM has most complete portfolio of nutritional ingredients






Offering complete solutions – "more than an ingredients provider"

DSM is a reliable, end-to-end, innovative, purpose-led partner powered by experts to deliver science-backed nutrition and health products and quality customized solutions





Rapid developments in science & technology enable DSM to add next frontier to business model





DSM extended its unique business model with 3rd muscle Added "Precision" and "Personalization", powered by Data & Bioscience

Precision & Personalization Digitization & Bioscience as a know-how multiplier



Global Products Science, Scale, Quality



Local Solutions

DSM has a rich innovation pipeline, predominantly bioscience-based **DSM's total innovation pipeline targeted to add 1.5% annually to sales growth and 2.5% to** Adj. EBITDA growth for period up to 2025

Growth Themes		Business Platforms	Examples of larger projects
Precision Digitally enabled business models	Î	Personalized Nutrition	Hologram Sciences Inc.
	`	Precision Animal Farming	Verax (w/ Inside Tracker), Sustell (w/ Blonk)
Prevention Healthy solutions provided by nature	İ	Health from the Gut	Probiotics, Prebiotics (e.g., Glycom human milk oligos), Vitamin Direct
	İ	Immunity	Ampli-D
	Î	Brain Health	CBDs/CBX (w/ Brains)
	Î	Sugar reduction	Avansya (fermentative stevia) (w/ Cargill)
		Antibiotics Reduction / ANH Gut Health	Eubiotic enzymes (w/ Novozymes); Designer prebiotics (w/ Midori)
Proteins Driving adoption of more sustainable proteins to feed the population	Ĥ	Sustainable Food Proteins	CanolaPro (w/ Avril) and pea proteins (Vestkorn) for meat and dairy alternatives
	`	Animal Emission Reduction	Bovaer
	.	Low-footprint Feed Proteins	2 nd Gen Protease, 4 th Gen Phytase, Cornzyme (w/ Novozymes)
Pathways Sustainable ingredient manufacturing		Sustainable Lipids Animal	Veramaris
		Sustainable Lipids Human	Green Ocean Human; Pharma Customized Lipids;



Examples of DSM's rich innovation pipeline addressing global food system challenges, contributing to sustainable growth

Supporting the Immunity of people with micronutrient supplements

- COVID-19 has highlighted the need for easily accessible dietary solutions that support proactive immune health: sufficient nutrient intake is vital for people's immunity
- Nutritional ingredients including Quali®-C, Quali®-D, Quali®-B, life's™OMEGA, ampli-D®, Culturelle®
- Available in reliable and efficacious formulations, premixes, market-ready solutions, B2C



Nutritious, tasty and sustainably produced plant-based meat, dairy and fish alternatives

- Authentic taste
- Compelling texture & mouthfeel
- Improve nutritional profile
- Managed salt, sugar, fat, allergens



EVERSWEET™ Stevia: Calorie-free sweetness, inspired by nature

- · Reduced- and zero-calorie options for food & beverage
- No compromise on taste.
- · Support good health and well-being in our societies
- Consumer end-products launched successfully by our customers, with many more product development projects underway



Bovaer[™] - Reducing emissions from livestock

- Reducing methane emissions from ruminants by at least 30%
- Helping the dairy and beef value chain to significantly de-carbonize
- Supporting sustainable animal farming
- Regulatory approvals in Brazil and Chile and a positive EFSA opinion in Europe
- Large scale production capacity planned in Dalry, UK by 2025




Veramaris[®] - reducing our reliance on marine resources

- Contributing to preserving marine biodiversity
- Fatty Omega-3 acids EPA & DHA
- 1kg Veramaris oil is equivalent to 60kg wild catch
- introduction of the product for shrimp farming, pet food and human nutrition







improve the sustainability of animal protein

 Providing accurate, globally recognized, comparable analyses and results of environmental impact assessments, interventions and improvements throughout the animal protein value chain





 $\mathbf{\alpha}$

Sustell[™] - a powerful solution to measure, compare and





- Essential for health Human & Animal:



DSM has the capability and therefore the responsibility to make a meaningful impact on the global food systems, while this also creates exciting new market opportunities

17 FOR THE GOALS

15 UFE ON LAND

10 REDUCED INEQUALITIES

INDUSTRY, IM AND INFRAST

14 INFE BELOW WAITER

12 ESPONSIE AND PRODUCT

13 CLIMATE

.......................

8 DECENT WORK AND ECONOMIC GROWTH 4 QUALITY EDUCATION

G CLEAN WATER AND SANITATION



Transformation DSM into to a fully focused Health, Nutrition & Bioscience company

- Materials businesses managed largely on a standalone basis; reviewing strategic options, including a possible change of ownership
- New simplified Health, Nutrition & Bioscience organization through:
 - Creation of 3 Business Groups with strong market focus
 - Food & Beverage
 - Health, Nutrition & Care
 - Animal Nutrition & Health
 - Integration of innovation activities of DSM Innovation Center in 3 Business Groups: Fully equipped to drive impactful innovations
 - Alignment of global enabling functions and top structure



Three Business Groups created with clear end-market orientation and large addressable markets





2021 Performance

Royal DSM



DSM's strategy is to deliver strong financial returns, creating a positive societal impact, while having best-in-class ESG performance

Global food systems face huge environmental and societal challenges and offer opportunities







Biotechnology Data & Digital breakthroughs

Precision & Personalization DSM is uniquely positioned and has the capabilities to address these opportunities Rich innovation pipeline



Great People, unique Culture



This creates purpose-led

Building a company that delivers long-term, performance-driven profitable growth

> Ambitious mid-term profit targets

Mid-single-digit % organic sales growth


Adj. EBITDA margins >20%

High-single digit % annual Adj. EBITDA growth




Taking full responsibility for our OWN footprint and people

ESG ambitions (set in 2019) accelerated in 2021





Quantifiable and auditable food system commitments set for 2030





Group | Strong full year 2021 results



- Strong full year results and strong performance on non-financial targets,
- Further step-up in sustainability ambitions and a more aggressive path towards net-zero
- Net profit of €1,680m, including profits from sale of AOC and Resins & Functional Materials (versus Net Profit 2020 of €508m)



Nutrition | Strong Results – Demonstrating its superior operational performance and reliability as a supplier



- Successfully navigating significant supply chain and logistic disruptions affecting the market throughout the year
- Strong 8% Adjusted EBITDA growth largely related to increased volumes, with a 6% contribution from M&A and a 4% negative FX effect






Materials | Very strong performance



- Volumes up +14% vs 2020 and +6% vs 2019, while markets continued to struggle with semiconductor shortages and supply chain disruptions
- Adj. EBITDA up +60% vs 2020 and +17% vs 2019
- Results supported by customer restocking, operational leverage, manufacturing excellence and good pricing strength



* Continuing Operations




DSM made four important acquisitions in 2021

- F&F bio-based intermediates business of Amyris, Inc., extending offerings in Personal Care & Aroma Ingredients with annual sales of about €20m
- Full ownership of Midori USA, Inc., a biotechnology start-up developing targeted eubiotics for animals
- First Choice Ingredients, a leading US supplier of dairy-based savory flavorings for a wide range of F&B applications including plant-based alternatives with annual sales of about €70m
- Vestkorn Milling, a leading producer of pea- and bean-derived ingredients for plant-based protein products with annual sales of about €20m
- DSM also divested businesses in 2021:
 - It completed the sale of Resins & Functional Materials and associated businesses
 - Divestment of its stake in AOC



Other 2021 Financial Highlights



* Including M&A, ROCE Continuing Operations was 11.2%, up 70bps compared to 2020 (10.4%)

Purpose-led, Performance-driven (Nutrition '07-'21)

Ambitious mid-term profit targets:


Mid-single digit % organic sales growth

Adj. EBITDA margins >20%

High-single digit % annual adjusted EBITDA growth

~ 10% avg. annual increase in Adj. Net Operating Free Cash Flow

Adj. EBITDA growth CAGR 07-'21 +10%




*2018 figures show the results of the underlying business. This excludes an estimated €295m additional Adjusted EBITDA contribution from an exceptional temporary vitamin price environment, due to a force majeure situation in the industry. See Integrated Annual Report 2018.




Creating sustainable value for all stakeholders Superior share price performance vs. peers and AEX

Stock Performance % (since Jan-2017)

DSM achieved superior share price performance over the last 5 years



Dividend €



Note: Peers include Symrise, Givaudan, Kerry, IFF, Novozymes, Chr Hansen. Share prices rebased to 100. (1) Share price change between 1st January 2017 and end of Q1 2022

Ødsm


2022 Q1 & Outlook



Q1 Results Highlights: DSM delivered a good first quarter



- Group sales +18%
- Robust demand across DSM's
 businesses
- Effective pricing measures to counteract inflation throughout the value chain
- Excellence of DSM's people and operations ensured DSM was able to continue to satisfy its customers' needs



- HNB sales +16%
- Despite highly inflationary environment and ongoing global supply chain challenges, all businesses delivered a good quarter



- Materials Sales +25%
- On April 20, 2022, DSM announced agreement to sell DSM Protective Materials to Avient Corporation for an Enterprise Value of €1.44bn



Full Year 2022 outlook unchanged

• DSM expects for its Health, Nutrition & Bioscience activities to deliver a high-single digit Adjusted EBITDA increase

• For the Group, DSM expects a mid-single digit Adjusted EBITDA increase, with a high-single Adjusted Net Operating Free Cash Flow increase. This outlook is based on DSM's expectation of a stable Adjusted EBITDA in Materials following the strong performance in 2021



BRIGHT SCIENCE. BRIGHTER LIVING.™